Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5O4GR)

Drug Name
NB1011 Drug Info
Synonyms
Thymectacin; BVDU prodrug; NB1011; UNII-2ZRZ4TSW3F; 2ZRZ4TSW3F; 5-(2-Bromovinyl)-2'-deoxy-5'-uridyl-phenyl-alanylphosphoramidate, trans-; (E)-5-(2-Bromovinyl)-2'-deoxy-5'-uridyl phenyl L-methoxyalaninylphosphoramidate; L-Alanine, N-(5-((1E)-2-bromoethenyl)-2'-deoxy-P-phenyl-5'-uridylyl)-, methyl ester; E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(L-methylalaninyl)-phenylphosphoramidate; 232925-18-7; Brivudine phosphoramidate; AC1O5U63; SCHEMBL13904642; DTXSID00177862; NB-1011; NB 1011; DB05116; LS-181955; J3.616.614B; methyl (2S)-2
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 1/2 [1]
Cross-matching ID
PubChem CID
6440764
CAS Number
CAS 232925-18-7
TTD Drug ID
DM5O4GR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [3]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [4]
Pemetrexed DMMX2E6 Central nervous system lymphoma 2B33.5 Approved [5]
Trifluridine DMG2YBD Herpetic keratitis 1F00.10 Approved [6]
Capecitabine DMTS85L Adenocarcinoma 2D40 Approved [7]
Raltitrexed DMT9K8G Rectal adenocarcinoma 2B92 Approved [8]
Floxuridine DM04LR2 Colorectal cancer 2B91.Z Approved [9]
Flucytosine DM13VTW Cryptococcal meningitis Approved [10]
Nolatrexed DMOF0CA Solid tumour/cancer 2A00-2F9Z Phase 3 [11]
Plevitrexed (R)-isomer DMTL39C Gastric adenocarcinoma 2B72 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Thymidylate synthase (Candi TMP1) TTU6BFZ TYSY_CANAL Binder [2]

References

1 ClinicalTrials.gov (NCT00248404) NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS). U.S. National Institutes of Health.
2 Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300.
3 The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
4 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
5 Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
6 Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
7 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
8 DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
9 Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
10 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
11 A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
12 Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.